AR054782A2 - Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico - Google Patents
Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diureticoInfo
- Publication number
- AR054782A2 AR054782A2 ARP060102579A ARP060102579A AR054782A2 AR 054782 A2 AR054782 A2 AR 054782A2 AR P060102579 A ARP060102579 A AR P060102579A AR P060102579 A ARP060102579 A AR P060102579A AR 054782 A2 AR054782 A2 AR 054782A2
- Authority
- AR
- Argentina
- Prior art keywords
- diuretic
- irbesartan
- combination
- pharmaceutical compositions
- tablets containing
- Prior art date
Links
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title abstract 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002198 irbesartan Drugs 0.000 title abstract 4
- 239000002934 diuretic Substances 0.000 title abstract 3
- 230000001882 diuretic effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas que contienen irbesartan en combinacion con un diurético, y que proveen tabletas que contienen una elevada cantidad de agente activo y que gozan de excelentes propiedades de humectacion y desintegracion. Reivindicacion 1: Una composicion farmacéutica, caracterizada porque comprende basado en peso: (a) 20 a 70 %, de irbesartan o una de sus sales farmacéuticamente aceptables; (b) 2 a 33 %, de diurético, siendo la carga combinada de (a) y (b), no superior al 85%; (c), 1 a 70 %, de diluyente; (d) 2 a 20 %, de ligante; (e) 1 a 10 %, de desintegrante, (f) 0,1 a 5 % de antiadherente; y (g) 0,2 a 5 % de lubricante, uno o mas excipientes farmacéuticamente aceptables, en donde una tableta formada a partir de dicha composicion tiene una velocidad de disolucion tal que aproximadamente de 80 % o más, del irbesartan o de sus sales del mismo, contenido en dicha tableta, se disuelve en el lapso de 30 minutos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47261895A | 1995-06-07 | 1995-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054782A2 true AR054782A2 (es) | 2007-07-18 |
Family
ID=23876256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR10297996A AR002350A1 (es) | 1995-06-07 | 1996-06-06 | Composiciones farmacéuticas que contienen irbesartan |
| ARP060102579A AR054782A2 (es) | 1995-06-07 | 2006-06-16 | Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR10297996A AR002350A1 (es) | 1995-06-07 | 1996-06-06 | Composiciones farmacéuticas que contienen irbesartan |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0747050B2 (es) |
| JP (1) | JP3162626B2 (es) |
| KR (1) | KR100442719B1 (es) |
| CN (1) | CN1149083C (es) |
| AR (2) | AR002350A1 (es) |
| AT (2) | ATE248594T1 (es) |
| AU (1) | AU702651B2 (es) |
| CA (1) | CA2177772C (es) |
| CZ (1) | CZ291532B6 (es) |
| DE (2) | DE69638348D1 (es) |
| DK (2) | DK1275391T3 (es) |
| ES (2) | ES2205000T5 (es) |
| HK (1) | HK1002384A1 (es) |
| HU (1) | HU229369B1 (es) |
| IL (1) | IL118309A (es) |
| NO (2) | NO310495B1 (es) |
| NZ (2) | NZ329547A (es) |
| PL (1) | PL184893B1 (es) |
| PT (2) | PT747050E (es) |
| RU (2) | RU2210368C1 (es) |
| SG (1) | SG49956A1 (es) |
| TW (1) | TW442301B (es) |
| ZA (1) | ZA964337B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6517871B1 (en) * | 1998-07-20 | 2003-02-11 | Smithkline Beecham Corporation | Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AU7649100A (en) | 1999-08-30 | 2001-03-26 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| JP4565456B2 (ja) * | 1999-11-02 | 2010-10-20 | 塩野義製薬株式会社 | 着色顆粒の色素定着法 |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
| TR200301553A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
| JP2005126338A (ja) * | 2003-10-21 | 2005-05-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 心不全治療剤 |
| WO2005089720A1 (en) * | 2004-03-10 | 2005-09-29 | Ranbaxy Laboratories Limited | Valsartan tablets and the process for the preparation thereof |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| WO2006013545A1 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of irbesartan |
| RU2424805C2 (ru) | 2005-09-12 | 2011-07-27 | Актелион Фармасьютиклз Лтд | Стабильные фармацевтические композиции, включающие пиримидинсульфамид |
| KR20140053419A (ko) * | 2005-11-17 | 2014-05-07 | 노파르티스 아게 | 약제학적 조성물 |
| ATE462414T1 (de) * | 2006-01-09 | 2010-04-15 | Krka D D Novo Mesto | Irbesartan enthaltende feste zubereitung |
| DE102006006588A1 (de) * | 2006-02-13 | 2007-08-16 | Ratiopharm Gmbh | Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung |
| TWI351399B (en) * | 2006-06-12 | 2011-11-01 | Schering Corp | Pharmaceutical formulations and compositions of a |
| WO2007144175A2 (en) | 2006-06-16 | 2007-12-21 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| WO2008125388A1 (en) * | 2007-04-17 | 2008-10-23 | Ratiopharm Gmbh | Pharmaceutical compositions comprising irbesartan |
| JP5683058B2 (ja) * | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
| TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| ES2349317T3 (es) | 2007-11-28 | 2010-12-29 | Laboratorios Lesvi, S.L. | Formulaciones farmacéuticas que contienen irbesartán. |
| CN101327213B (zh) * | 2008-06-20 | 2010-10-13 | 海南锦瑞制药股份有限公司 | 厄贝沙坦氢氯噻嗪药用组合物及其制备方法 |
| JP5296456B2 (ja) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
| WO2011001202A1 (en) * | 2009-06-30 | 2011-01-06 | Sanofi-Aventis | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| WO2011010316A1 (en) * | 2009-07-20 | 2011-01-27 | Hetero Research Foundation | Pharmaceutical compositions of irbesartan |
| FI2498756T4 (fi) * | 2009-11-09 | 2023-03-22 | Neratinibimaleaatin tablettiformulaatiot | |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| JP4974255B2 (ja) * | 2010-03-16 | 2012-07-11 | 塩野義製薬株式会社 | アンジオテンシンｉｉ受容体拮抗剤の配合剤 |
| JP5459670B2 (ja) * | 2010-05-07 | 2014-04-02 | 塩野義製薬株式会社 | 着色顆粒の色素定着化剤 |
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| WO2012003987A1 (en) * | 2010-07-08 | 2012-01-12 | Ratiopharm Gmbh | Oral dosage form of deferasirox |
| JP6081376B2 (ja) * | 2011-12-28 | 2017-02-15 | ニプロ株式会社 | アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物 |
| WO2013172297A1 (ja) | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤 |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| JP5714652B2 (ja) * | 2013-06-13 | 2015-05-07 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| JP6238921B2 (ja) * | 2014-02-17 | 2017-11-29 | 大原薬品工業株式会社 | イルベサルタンを含有する錠剤 |
| JP5978335B2 (ja) * | 2015-03-11 | 2016-08-24 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| JP6199922B2 (ja) * | 2015-03-20 | 2017-09-20 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
| JP6445923B2 (ja) * | 2015-04-22 | 2018-12-26 | ダイト株式会社 | イルベサルタン含有錠剤の調製方法 |
| JP6737060B2 (ja) * | 2015-09-11 | 2020-08-05 | ニプロ株式会社 | イルベサルタンを含有する医薬組成物の製造方法 |
| JP6151413B2 (ja) * | 2016-07-25 | 2017-06-21 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| JP2017141299A (ja) * | 2017-05-24 | 2017-08-17 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| JP6233911B2 (ja) * | 2017-08-22 | 2017-11-22 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
| JP2018009032A (ja) * | 2017-10-19 | 2018-01-18 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
| CN108434112A (zh) * | 2018-06-08 | 2018-08-24 | 华益药业科技(安徽)有限公司 | 一种厄贝沙坦片及其制备方法 |
| JP2018168185A (ja) * | 2018-07-05 | 2018-11-01 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| PH12018000390A1 (en) * | 2018-11-20 | 2020-09-28 | Novex Science Pte Ltd | Carbocysteine and zinc tablet |
| JP2019203031A (ja) * | 2019-09-06 | 2019-11-28 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3744317C1 (de) | 1987-12-28 | 1989-05-24 | Rudolf Dr Rer Nat Kuerner | Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe |
| CA2016710A1 (en) | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
| US5164407A (en) | 1989-07-03 | 1992-11-17 | Merck & Co., Inc. | Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists |
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| TW201738B (es) * | 1990-03-20 | 1993-03-11 | Sanofi Co | |
| IL99372A0 (en) * | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
| CA2229000C (en) | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
| WO1994009778A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
| EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
| US5541209A (en) * | 1994-08-22 | 1996-07-30 | Bristol-Myers Squibb Company | Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative |
| FR2725987B1 (fr) * | 1994-10-19 | 1997-01-10 | Sanofi Sa | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
-
1996
- 1996-05-16 TW TW085105820A patent/TW442301B/zh not_active IP Right Cessation
- 1996-05-17 NZ NZ329547A patent/NZ329547A/en not_active IP Right Cessation
- 1996-05-17 NZ NZ286612A patent/NZ286612A/en not_active IP Right Cessation
- 1996-05-17 IL IL11830996A patent/IL118309A/xx not_active IP Right Cessation
- 1996-05-27 SG SG1996009899A patent/SG49956A1/en unknown
- 1996-05-28 ZA ZA9604337A patent/ZA964337B/xx unknown
- 1996-05-30 CA CA002177772A patent/CA2177772C/en not_active Expired - Fee Related
- 1996-06-05 CZ CZ19961634A patent/CZ291532B6/cs not_active IP Right Cessation
- 1996-06-05 KR KR1019960019949A patent/KR100442719B1/ko not_active IP Right Cessation
- 1996-06-06 NO NO19962387A patent/NO310495B1/no not_active IP Right Cessation
- 1996-06-06 RU RU2001130903/14A patent/RU2210368C1/ru active
- 1996-06-06 AR AR10297996A patent/AR002350A1/es not_active Application Discontinuation
- 1996-06-06 RU RU96111030/14A patent/RU2181590C2/ru active
- 1996-06-06 AU AU54763/96A patent/AU702651B2/en not_active Ceased
- 1996-06-06 HU HU9601564A patent/HU229369B1/hu not_active IP Right Cessation
- 1996-06-07 PT PT96304291T patent/PT747050E/pt unknown
- 1996-06-07 DE DE69638348T patent/DE69638348D1/de not_active Expired - Lifetime
- 1996-06-07 DK DK02016237.6T patent/DK1275391T3/da active
- 1996-06-07 ES ES96304291T patent/ES2205000T5/es not_active Expired - Lifetime
- 1996-06-07 PL PL96314670A patent/PL184893B1/pl unknown
- 1996-06-07 PT PT02016237T patent/PT1275391E/pt unknown
- 1996-06-07 CN CNB961068329A patent/CN1149083C/zh not_active Expired - Lifetime
- 1996-06-07 EP EP96304291A patent/EP0747050B2/en not_active Expired - Lifetime
- 1996-06-07 AT AT96304291T patent/ATE248594T1/de active
- 1996-06-07 EP EP02016237A patent/EP1275391B1/en not_active Expired - Lifetime
- 1996-06-07 ES ES02016237T patent/ES2363127T3/es not_active Expired - Lifetime
- 1996-06-07 DK DK96304291.6T patent/DK0747050T4/da active
- 1996-06-07 DE DE69629755T patent/DE69629755T3/de not_active Expired - Lifetime
- 1996-06-07 AT AT02016237T patent/ATE503478T1/de active
- 1996-06-07 JP JP14557996A patent/JP3162626B2/ja not_active Expired - Lifetime
-
1998
- 1998-01-27 HK HK98100693A patent/HK1002384A1/xx not_active IP Right Cessation
-
2000
- 2000-09-22 NO NO20004743A patent/NO310393B1/no not_active IP Right Cessation
-
2006
- 2006-06-16 AR ARP060102579A patent/AR054782A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054782A2 (es) | Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico | |
| BR0003158A (pt) | Formulação de dosagem oral de derretimentoinstantâneo | |
| DE60019693D1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| HK1010722A1 (en) | Benzoyl guanidines, their production and their use in medicaments | |
| DE69942610D1 (de) | Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen | |
| IL111647A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them | |
| NO960973D0 (no) | Mikropartikler inneholdende aktive materialer og gass | |
| BR9509019B1 (pt) | comprimido isento de solventes orgÂnicos. | |
| AR013117A1 (es) | Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral | |
| RS50303B (sr) | Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem | |
| UA81615C2 (ru) | Фармацевтическая композиция, которая содержит метформин и глибенкламид, для лечения диабета типа ii | |
| CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
| ES2111547T3 (es) | Comprimido de liberacion prolongada. | |
| ES2080497T3 (es) | Bloques para la limpieza de inodoros. | |
| PA8388101A1 (es) | Tableta de liberacion controlada. | |
| RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
| AR070017A1 (es) | Una composiciones de liberacion prolongada que comprende micofenolato sodico,el metodo de utilizar dicha composicion y el uso de dicha composicion | |
| AR018607A1 (es) | Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion | |
| BR0013106A (pt) | Composição farmacêutica flutuante, comprimido, e processo de prepapação de um comprimido. | |
| BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
| AU2003275875A1 (en) | Edible dissolving gelatin strips | |
| ATE331502T1 (de) | 4-amino-1-hydroxybutyliden-1,1-biphosphonsäure enthaltende direktkomprimierte tablette | |
| AP1485A (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| FI963567A0 (fi) | Diklofenakki-Na:a sisältävä depottabletti |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |